MX2019006005A - Metodos para la deteccion de cancer. - Google Patents

Metodos para la deteccion de cancer.

Info

Publication number
MX2019006005A
MX2019006005A MX2019006005A MX2019006005A MX2019006005A MX 2019006005 A MX2019006005 A MX 2019006005A MX 2019006005 A MX2019006005 A MX 2019006005A MX 2019006005 A MX2019006005 A MX 2019006005A MX 2019006005 A MX2019006005 A MX 2019006005A
Authority
MX
Mexico
Prior art keywords
methods
detection
cancer detection
cancer
biomarker
Prior art date
Application number
MX2019006005A
Other languages
English (en)
Spanish (es)
Inventor
Feldman Robert
MAHTANI Melanie
Original Assignee
Prime Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prime Genomics Inc filed Critical Prime Genomics Inc
Publication of MX2019006005A publication Critical patent/MX2019006005A/es

Links

Classifications

    • G01N33/57515
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2019006005A 2016-11-22 2017-11-22 Metodos para la deteccion de cancer. MX2019006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425549P 2016-11-22 2016-11-22
PCT/US2017/063157 WO2018098379A1 (en) 2016-11-22 2017-11-22 Methods for cancer detection

Publications (1)

Publication Number Publication Date
MX2019006005A true MX2019006005A (es) 2019-10-02

Family

ID=62195635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006005A MX2019006005A (es) 2016-11-22 2017-11-22 Metodos para la deteccion de cancer.

Country Status (8)

Country Link
US (1) US20200081008A1 (enExample)
EP (1) EP3544605A4 (enExample)
JP (2) JP2020511933A (enExample)
CN (1) CN110198711A (enExample)
CA (1) CA3044257A1 (enExample)
MA (1) MA46927A (enExample)
MX (1) MX2019006005A (enExample)
WO (1) WO2018098379A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044257A1 (en) * 2016-11-22 2018-05-31 Prime Genomics, Inc. Methods for cancer detection
CN108830045B (zh) * 2018-06-29 2021-04-20 深圳先进技术研究院 一种基于多组学的生物标记物系统筛选方法
KR102211972B1 (ko) * 2018-08-02 2021-02-04 엑소젠 피티이. 엘티디 액체생검 다중 암 유전자 바이오마커를 이용한 유방암 조기진단 및 치료 후 모니터링 방법
WO2020180896A1 (en) * 2019-03-03 2020-09-10 Purdue Research Foundation Systems and methods for identifying subtype, prognosis and monitoring of breast cancer
CN111679076A (zh) * 2020-06-15 2020-09-18 吉林医药学院 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒
US20210388451A1 (en) * 2020-06-16 2021-12-16 Grail, Inc. Methods for analysis of cell-free rna
CN111979321B (zh) * 2020-08-26 2022-07-12 郑州大学第一附属医院 用于胰腺癌检查的基因标记物
EP4208712A4 (en) * 2020-09-01 2024-12-11 Oncodea Corporation PREDICTIVE DIAGNOSTIC TEST FOR EARLY DETECTION AND MONITORING OF DISEASE
CN115927610B (zh) * 2022-07-19 2024-11-05 武汉艾米森生命科技有限公司 检测foxo6基因中目标区域的甲基化水平的试剂在制备膀胱癌诊断产品中的应用
WO2025005966A1 (en) * 2023-06-29 2025-01-02 Edge Animal Health, Inc. Urine pcr assay and use thereof to diagnose and stage feline chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6358683B1 (en) * 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
JP2008073304A (ja) * 2006-09-22 2008-04-03 Gifu Univ 超音波乳房診断システム
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011100472A1 (en) * 2010-02-10 2011-08-18 The Regents Of The University Of California Salivary transcriptomic and proteomic biomarkers for breast cancer detection
CA2803266A1 (en) * 2010-07-08 2012-01-12 Prime Genomics, Inc. System for the quantification of system-wide dynamics in complex networks
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR101335034B1 (ko) * 2011-08-25 2013-12-02 주식회사 바이오인프라 유방암 진단을 위한 엑소좀 내의 ANT2 mRNA의 이용방법
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2015187727A2 (en) * 2014-06-04 2015-12-10 Atossa Genetics Inc. Molecular mammography
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
CA3044257A1 (en) * 2016-11-22 2018-05-31 Prime Genomics, Inc. Methods for cancer detection

Also Published As

Publication number Publication date
MA46927A (fr) 2019-10-02
JP2020511933A (ja) 2020-04-23
EP3544605A4 (en) 2020-11-25
WO2018098379A1 (en) 2018-05-31
CN110198711A (zh) 2019-09-03
US20200081008A1 (en) 2020-03-12
CA3044257A1 (en) 2018-05-31
EP3544605A1 (en) 2019-10-02
JP2022163076A (ja) 2022-10-25

Similar Documents

Publication Publication Date Title
MX2019006005A (es) Metodos para la deteccion de cancer.
EP3732626A4 (en) ALWAYS ACTIVE KEYWORD DETECTOR
IL261468A (en) Uterine cancer treatments
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
MX2016009862A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
PL3455631T3 (pl) Sposoby klasyfikowania pacjentów z nowotworem litym
ECSP17015977A (es) Terapia de combinacion
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
EP3459140A4 (en) FREE SPACE SEGMENT TESTER (FSST)
MX2016004865A (es) Metodo y dispositivo para analizar relacion social.
EP3208605C0 (en) INSPECTION DEVICE USING A THZ BAND
AU360070S (en) Automatic access gate
IL264359A (en) Combination test for colorectal cancer
MX2017001686A (es) Anticuerpos anti-ceramida.
MX2017012553A (es) Compuestos espirociclicos.
DK3277284T3 (da) Hidtil ukendte terapier mod kræft
DK3198034T3 (da) Biomarkører for cervixcancer
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
GB201420141D0 (en) Retractor with improved light source, and light source for an improved retractor
HUE059560T2 (hu) Elõrehaladott rákban szenvedõ alanyok részére való aktivált dendritikus sejtkészítményekkel kapcsolatos eljárások
IL262202B (en) Photodetector with helmholtz resonator